By Molly Wen
LianBio (LIAN.US) was a rising star of the Chinese pharmaceutical scene but the drugs startup has flamed out just four years after its launch.
The biotech’s abbreviated lifespan underscores the challenges and costs of bringing novel drugs to the market, even with financial backing and big ambitions.
您已閱讀5%（311字），剩余95%（5496字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。